Glaxosmithkline Share News (GSK)

First Zantac cancer risk trial in Calif. postponed five months

Feb 23 (Reuters) - The first scheduled trial over claims that GSK Plc's heartburn drug Zantac caused cancer, which had been set to begin Monday, has been postponed by five months.

Flu experts gather with H5N1 risk on the agenda

LONDON, Feb 24 (Reuters) - The world's leading experts on influenza met this week to discuss the threat posed to humans by a strain of H5N1 avian flu that has caused record numbers of bird deaths around the world in recent months.

Upbeat corporate guidances lift European shares, Nvidia forecast boosts chip stocks

UK healthcare giants fall on ex-dividend trades

*

FTSE 100 slips as ex-dividend trades weigh, Rolls-Royce soars

Rolls-Royce jumps on upbeat forecast

*

LONDON MARKET CLOSE: FTSE 100 struggles, but European peers rise

(Alliance News) - Stock prices in London closed mixed on Thursday, with blue-chips ending in the red on renewed concerns of higher rates in the US, as well as a host of stocks going ex-dividend.

GSK, Pfizer venture says HIV injectable therapy preferred in trial

(Alliance News) - GSK PLC on Thursday said that ViiV Healthcare has found that its injectable Cabenuva is as effective as the daily oral Biktarvy in treating HIV-1.

GSK's ViiV says trial indicates HIV shot as effective as rival Gilead pill

(Sharecast News) - UK pharma firm GSK's HIV treatment division, ViiV Healthcare, said its HIV injection treatment was as effective as a daily pill made by Gilead Sciences.

GSK's ViiV says study shows its long-acting HIV shot as effective as Gilead's daily pill

LONDON, Feb 22 (Reuters) - British drugmaker GSK's HIV treatment division, ViiV Healthcare, published data on Wednesday showing its long-acting HIV injection is as effective as the market-leading daily pill made by Gilead Sciences Inc.

GSK, Pfizer joint venture gets EU marketing approval for HIV treatment

(Alliance News) - ViiV Healthcare on Wednesday said it received marketing authorisation from the European Commission for Triumeq PD, a treament for children living with HIV

Judge weighs key evidence ahead of first Zantac cancer trial

Feb 16 (Reuters) - Lawyers for a man who alleges he developed bladder cancer after taking GSK Plc's heartburn drug Zantac urged a California judge on Thursday to allow expert testimony linking the drug to the illness at an upcoming trial.

Judge to weigh key evidence ahead of first Zantac cancer trial

Feb 16 (Reuters) - GSK Plc is expected to urge a California judge on Thursday to limit what expert testimony jurors can hear in the first trial over claims that the company's heartburn drug Zantac caused cancer.

Pfizer/BioNTech, Moderna gear up for 2024 London trial over COVID vaccine patents

LONDON, Feb 16 (Reuters) - Pfizer Inc and its German partner BioNTech SE are gearing up for a 2024 trial with Moderna Inc at London's High Court in competing patent lawsuits over their rival COVID-19 vaccines.

UK dividends calendar - next 7 days

GSK hails positive phase III trial results for RSV vaccine candidate

(Alliance News) - GSK PLC on Thursday said a New England Journal of Medicine publication announced positive phase III trial results for its respiratory syncytial virus vaccine candidate for older adults.

embargoed-Britain's NICE to speed up reviews of COVID-19 treatments

LONDON, Feb 16 (Reuters) - Britain's agency that determines if medicines should be used in the National Health Service (NHS) said on Thursday it is speeding up how it decides if COVID-19 therapies are still effective against circulating variants.